TG Therapeutics Receives National Contract With The Department Of Veterans Affairs For Briumvi (Ublituximab) To Be The Preferred Agent Listed On VA National Formulary For Anti-CD20 Antibody Indications For Relapsing Forms Of Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics announced that Briumvi (Ublituximab), its treatment for relapsing forms of multiple sclerosis, has been selected as the preferred agent on the VA National Formulary for anti-CD20 antibody indications. This national contract with the Department of Veterans Affairs marks a significant milestone for the company, potentially increasing the drug's usage and visibility within the VA healthcare system.
April 18, 2024 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics' Briumvi becoming the preferred agent for relapsing MS on the VA National Formulary could lead to increased usage and visibility, potentially boosting the company's revenue and market position.
Being selected as the preferred agent for a major healthcare system like the VA significantly enhances the drug's marketability and accessibility, likely leading to increased sales and a positive impact on TG Therapeutics' financials and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100